Skip to content
- Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
- Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N.
- Drugs R D. 2020 Mar 25. doi: 10.1007/s40268-020-00301-8. [Epub ahead of print]
- Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
- Testa U, Castelli G, Pelosi E.
- Med Sci (Basel). 2020 Mar 23;8(1). pii: E18. doi: 10.3390/medsci8010018.
- Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer.
- You Y, Li L, Lu J, Wu H, Wang J, Gao J, Wu M, Liang Z.
- Front Oncol. 2020 Mar 10;10:295. doi: 10.3389/fonc.2020.00295. eCollection 2020.
- Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer.
- Knowlson C, Haddock P, Bingham V, McQuaid S, Mullan PB, Buckley NE.
- Ther Adv Med Oncol. 2020 Mar 9;12:1758835920906047. doi: 10.1177/1758835920906047. eCollection 2020.
- Genomic Alteration in Metastatic Breast Cancer and Its Treatment.
- Li A, Schleicher SM, Andre F, Mitri ZI.
- Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-14. doi: 10.1200/EDBK_280463.